How Tylenol PM’s ‘Non-Habit’ Label Masked a Dangerous Dependency | Johnson & Johnsonn

📎 Source Note: Transparency is essential in journalism. The facts and figures presented in this article are derived directly from the legal filings in this case. A copy of which can be found at the bottom of this article. We encourage readers to review the primary source document for themselves.

Table of Contents

  1. Introduction
  2. A Cultural Obsession with Sleep
  3. Corporate Greed and the Rise of the Over-the-Counter Sleep-Aid Market
  4. A Wolf in Sheep’s Clothing
  5. Johnson & Johnson Services, Inc.’s “Non Habit-Forming” Claims
  6. Economic Fallout and Health Consequences
  7. Corporate Social Responsibility vs. Corporate Accountability
  8. Local Communities, Workers, and the Social Impact
  9. Neoliberal Capitalism and the Incentives to Harm
  10. The Legal Action: Plaintiff Goodson vs. Johnson & Johnson
  11. Detailed Allegations
    • 11.1 Nature of the Action
    • 11.2 Background and Pharmacology of Diphenhydramine
    • 11.3 The Rise of Diphenhydramine-Based Sleep-Aids
    • 11.4 The Alleged False “Non Habit-Forming” Labeling
  12. Countless Americans Trapped by the “Non Habit-Forming” Myth
  13. Wealth Disparity and the Sleep Aid Market
  14. Corporate Ethics and the Real-World Impact
  15. Consumers’ Advocacy: A Call for Social Justice
  16. Skepticism About Corporate Change
  17. The Road Toward True Accountability

1. Introduction

Welcome to a conversation about power, profit, and how a major corporation—Johnson & Johnson Services, Inc.—managed to entangle so many Americans in a web of false promises regarding a product that claimed to be “non habit-forming”. We’re going to drag into the harsh light all the rotting pieces of corporate corruption—particularly how a juggernaut in the pharmaceutical world allegedly used its brand might to convince us that its over-the-counter sleep-aid solution was safe, harmless, and definitely would not hook us into repetitive nightly use.

Yet the story, told through the lens of a class action lawsuit and set in the precarious reality of a heavily medicated, sleep-deprived America, is anything but harmless. Diphenhydramine—an “antihistamine turned nighttime hero”—sits at the heart of this fiasco. This is the same chemical found in Tylenol PM, Benadryl, and other multi-billion dollar bestsellers that promise consumers relief from restlessness, allergies, and minor aches. But that repeated, everyday usage has come under severe scrutiny. Indeed, one can’t claim a product is “non habit-forming” if a substantial body of research suggests otherwise.

This story has everything: corporate greed, neoliberal capitalism, wealth disparity, corporate social responsibility used as a shield, and the devastating economic fallout from a pharmaceutical empire that’s allegedly more interested in shareholder returns than in ensuring consumers don’t end up in endless cycles of habitual use. Through the vantage point of one legal plaintiff, Sirreon Goodson, who purchased Tylenol PM multiple times only to discover it was not, in fact, “non habit-forming,” we dive headfirst into the lawsuit, the scandal, and the broader ramifications for corporate accountability in an era of unchecked power.

Brace yourselves, readers, because this is a 7,000-word epic that’ll tear apart the mythologies behind the public-relations spin, highlight the health and social consequences for local communities and workers, and ask the burning question: Do big corporations like Johnson & Johnson actually care about consumer health and well-being, or is this all just a performance in the name of maximizing profit?

2. A Cultural Obsession with Sleep

Before we examine the chilling truths behind diphenhydramine, it’s essential to appreciate the cultural tapestry into which the big pharmaceutical players wove their marketing spells. In 2023, a survey conducted by the American Academy of Sleep Medicine found that 22% of its 2,005 adult participants in the United States reported using over-the-counter sleep-aids. That’s nearly a quarter of the adult population. One in four people regularly looks for medical or over-the-counter solutions to get some shut-eye.

We are living in a sleepless world. We glorify hustle culture. We cram more tasks into fewer hours. We binge Netflix at midnight. We worry about global pandemics, climate catastrophes, and the never-ending demands of modern capitalism. The result? A national health crisis, with insomnia sitting comfortably at the top of a long list of ailments linked to everything from stress to obesity.

The quest for better sleep has become a multi-billion-dollar gold rush. And in that rush, corporations realized they could label and advertise so-called quick fixes with minimal accountability. Consumers, exhausted and desperate, were more than ready to open their wallets.

But something else began to unfold: the emergence of a health paradox. While many of these over-the-counter solutions are touted as quick, safe, and “non habit-forming,” the underlying reality can be drastically different. In the crosshairs of that difference stands Johnson & Johnson’s Tylenol PM, a product that aligns perfectly with the corporate narrative: “Our product will gently lull you to sleep, and we promise it won’t become a habit.”

This article aims to unmask that promise.

3. Corporate Greed and the Rise of the Over-the-Counter Sleep-Aid Market

The corporate world salivates at the sight of a captive consumer base—especially in times of crisis. If you can identify a need that millions of people share, from losing weight to quitting smoking or, in our case, falling asleep, you can exploit it. The big fish—companies like Johnson & Johnson Services, Inc.—thrive in neoliberal capitalism, raking in billions from the sleep industry. They promise a product that’s an easy fix, dangle it in front of consumers, and profit off the persistent cycle of repeated purchases.

We’ve seen it happen with opioids. We’ve seen it happen with sugary drinks. And now, over-the-counter sleep-aids might be marching down a strikingly similar path. The cost to society? Potential public health dangers, from unwitting addiction to severe side effects. Yet, behind every marketing push is the glitz of corporate branding campaigns that say: “We are a pillar of the community. We engage in corporate social responsibility. Look at our philanthropic contributions.”

But philanthropic contributions do not erase the systematic marketing of potentially habit-forming products to unsuspecting consumers. They do not offset the sly label “non habit-forming” plastered across countless packages. They do not, in any moral or ethical sense, excuse the manipulations at hand.

Why does all this matter? Because while the corporate executives enjoy their private jets and fill annual reports with glowing references to “corporate ethics,” the everyday consumer—particularly those on the lower end of the wealth disparity gap—ends up in a cycle of spending precious dollars on a solution that might ultimately harm them more than it helps.

4. A Wolf in Sheep’s Clothing

Diphenhydramine, widely recognized by the brand name Benadryl, first leaped into the U.S. market in 1946. Back then, the FDA was a different organization. The scientific rigor we expect of new drug approvals today barely existed. Almost from day one, the product was recognized for its sedating side effects. This got pharmaceutical companies thinking: “What if we can leverage that sedating side effect to market it as a sleep solution?”

Enter Johnson & Johnson and other corporate titans. They realized that with just a bit of “repackaging” and marketing, they could create a new line of products: nighttime, over-the-counter, “non habit-forming” sleep-aids. Marketers used bright colors on the box, put a trustworthy brand name on it, and told anxious, weary consumers: “Take this, and you’ll rest easy without fear of addiction.”

But even a cursory glance at medical journals or anecdotal experiences from thousands of people shows a dangerous truth: Diphenhydramine can indeed be habit-forming. This might initially manifest as tolerance (where the consumer needs ever-higher doses to achieve the same effect) and can lead to dependence or even psychological reliance. It’s also often underrated in terms of severe side effects, including sedation, confusion in older adults, and even delirium.

From a marketing perspective, the subtlety of the word “habit” in “non habit-forming” is cunning. Many consumers interpret that phrase as “I can take this regularly without consequences.” Meanwhile, data suggests quite the opposite. The rapid build-up of tolerance is a known phenomenon, and repeated usage isn’t something to shrug off. There’s a reason detox facilities now watch for diphenhydramine dependency. The “Benadryl challenge” fiasco on social media was a microcosm of the broader problem: people do, in fact, overuse and become dependent on such substances.

5. Johnson & Johnson Services, Inc.’s “Non Habit-Forming” Claims

The brand synergy of Johnson & Johnson is built on “trust.” Everyone from new mothers who buy baby lotion to the headache sufferer who picks up Tylenol sees the brand’s presence as comforting. But the lawsuit at hand—brought forth by Plaintiff Sirreon Goodson—reveals what can happen when that trust is broken.

Johnson & Johnson’s Tylenol PM is front and center in this crisis. Prominently displayed on the packaging is the phrase “non habit-forming,” implying, in no uncertain terms, that you can safely incorporate it into your bedtime routine. That’s the representation at the heart of this entire class action lawsuit. The claim, according to Goodson, is a flat-out lie because the product’s key ingredient, diphenhydramine, fosters a cycle of tolerance and dependence:

  1. Psychological Dependence: The consumer, hoping for a quick fix, starts to believe they “cannot sleep” without it.
  2. Increased Tolerance: After a week or two, the initial dosage is no longer effective, so the user increases the dose, heightening the risk of further dependence.
  3. Long-Term Harm: Extended use can result in a litany of side effects, from lingering grogginess and memory issues to, in certain demographics, more serious complications like delirium or a heightened risk of dementia.

Still, Johnson & Johnson allegedly chooses to plaster “non habit-forming” on every Tylenol PM box. If the allegations in the Goodson suit prove true, then we see the typical story of corporate greed trumping corporate ethics: Adopting a marketing claim that drives product sales, even if it misleads consumers.

6. Economic Fallout and Health Consequences

When a massive corporation mislabels or exaggerates the safety of its product, the economic fallout can be enormous. It’s not just about the direct cost of the product. It’s about:

  1. Healthcare Expenses: Doctor visits, potential detox programs, or extended counseling for those who find themselves psychologically dependent.
  2. Absenteeism: People might rely on these “non habit-forming” sleep-aids, only to wake up with hangover effects—leading to decreased productivity at work or missed days entirely. This ripple effect burdens the labor force.
  3. Ripple Impact on Families: Tolerance, dependence, or side effects from these drugs can create tension in households. Husbands, wives, and parents struggling with the mental and physical consequences of long-term diphenhydramine use cause stress and, at times, financial hardship.
  4. Insurance Premiums: If overuse or side effects require medical intervention, this can indirectly inflate insurance costs for entire communities.

Meanwhile, Johnson & Johnson rakes in billions of dollars in revenue. The resources it invests in disclaimers or accurate labeling often pale in comparison to advertising budgets. So we end up with a lopsided scenario: an entity so flush with resources that it can handle whatever fines or legal fees come its way, while lower- and middle-income consumers foot the real bill in the form of poorer health outcomes and drained savings.

From a corporate accountability standpoint, this misalignment of burdens exemplifies how large corporations operating under neoliberal capitalism can basically factor consumer harm into a cost-benefit calculation.

7. Corporate Social Responsibility vs. Corporate Accountability

Corporate executives at Johnson & Johnson will quickly point to their philanthropic donations, patient assistance programs, and the smiling faces on their corporate website to highlight their “corporate social responsibility.”

In an ideal world, “corporate social responsibility” includes sincere steps to avoid endangering customers, to commit to transparency in labeling, to consider the social cost of the product’s side effects, and to set aside profit motivations when they conflict with public safety. Yet, repeatedly, we see big business do the exact opposite. This Tylenol PM fiasco, as alleged by the complaint, demonstrates how a marketing label can be systematically repeated year after year without correction—despite a growing body of data suggesting that diphenhydramine can be dangerously habit-forming.

It’s not enough to quietly sponsor research or do a PR campaign about “raising awareness of sleep hygiene” if the fundamental product claims remain inaccurate. In the world of capitalism, accountability often only emerges when lawsuits or public scandals force the issue. The Goodson lawsuit is precisely such a nudge. But is it enough to spur real, systematic change within Johnson & Johnson?

8. Local Communities, Workers, and the Social Impact

Local communities shoulder the brunt of corporate misbehavior. The everyday worker who picks up Tylenol PM at the local pharmacy might soon face a mild or severe form of diphenhydramine dependence, lacking the resources to fully break free or even realize they have a problem.

Community Health Clinics might see an uptick in people complaining of chronic sleeplessness despite “using that Tylenol PM stuff.” Or older adults who start to experience confusion, memory lapses, or even early signs of dementia correlated to frequent use of first-generation antihistamines. The underinsured or unemployed, who can barely afford consistent health care, fall deeper into health crises.

Then there’s the economic ripple: small businesses might see productivity dives when employees arrive groggy or disoriented due to next-day sedation. Families might see tension grow around the dinner table if a spouse or parent grows mentally dependent on that nightly pill to cope. Because let’s face it, the phrase “non habit-forming” is psychologically powerful. It disarms the user. It says, “This is safe to use every night. Don’t worry.”

And so they do—night after night, for months, maybe years.

9. Neoliberal Capitalism and the Incentives to Harm

Under neoliberal capitalism, the overarching belief is that market solutions provide the best outcomes, innovation thrives under competition, and corporations that do harm will eventually be punished by the invisible hand of the market. If only that were entirely true in practice. The reality is that big brand recognition—like that of Johnson & Johnson—often shields a product from immediate consumer backlash. People trust the name. They see the label. They buy.

Incentives in this system prioritize short-term gains for shareholders. If a labeling approach, like “non habit-forming,” sells more product, well, that approach is going to be repeated. If a brand can avoid or delay any negative revelations, the bottom line will remain protected for years.

This lawsuit is not the first time we’ve seen the tension between profit and public health. It’s a classic story repeated across industries from tobacco to opioids to certain sugary beverages. The question we’re forced to ask: Is there truly any strong incentive for big pharmaceutical companies to stop “causing harm” when that harm is so profitable?

Johnson & Johnson stands tall among corporations that proclaim a devotion to “healthcare solutions.” But if the allegations in this lawsuit stand, can a company truly stand behind the ethics it professes?

10. The Legal Action: Plaintiff Goodson vs. Johnson & Johnson

Into this swirl of corporate power steps Plaintiff Sirreon Goodson. His story is that of countless Americans who struggle with insomnia or occasional sleeplessness—especially in a culture that rarely slows down. Goodson bought Tylenol PM at a Walmart and Walgreens in Sacramento, California. Before purchasing, he read the label “non habit-forming.” He believed it. He relied on it. Why wouldn’t he? If you can trust anyone with your over-the-counter meds, you’d think it’d be Johnson & Johnson.

Yet, Goodson found that after consistently using Tylenol PM, he developed a nightly routine—a habit. That’s exactly what Johnson & Johnson guaranteed wouldn’t happen. Feeling deceived, Goodson turned to the courts, bringing a class action complaint.

Key Allegations in the Complaint:

  1. Misrepresentation: The product’s labeling is prominently false, claiming “non habit-forming” even though diphenhydramine is known to cause tolerance and dependence.
  2. Damages: Consumers were led to believe they were purchasing a safer alternative to prescription sleep-aids, paying a premium or simply buying the product at all under false pretenses.
  3. Breaches of Warranty: The complaint lays out how Johnson & Johnson’s representations violate various consumer protection statutes and common-law claims, including express warranty, unjust enrichment, and fraud.
  4. Injunctive Relief: Goodson seeks not just personal damages but also an order forcing Johnson & Johnson to remove or correct the misleading label.

So we have a conflict that goes right to the heart of corporate accountability. A single phrase, “non habit-forming,” repeated thousands, maybe millions, of times on packaging and promotional materials has led potentially millions of Americans to put their trust—and money—into the brand.

11. Detailed Allegations

The complaint is not a haphazard piece of legalese. It’s quite thorough in painting a picture of scientific, medical, and consumer harm, referencing how diphenhydramine works, how it’s known to cause tolerance and dependency, and how that flies in the face of a “non habit-forming” claim.

11.1 Nature of the Action

  1. The plaintiff’s statement draws attention to the national obsession with sleep and how the CDC notes that more than a third of adults routinely don’t get enough of it.
  2. Over-the-counter solutions are now the go-to product for many suffering from insomnia. The complaint points to Johnson & Johnson’s marketing strategy, which allegedly contributed to creating an epidemic of habitual diphenhydramine usage.

11.2 Background and Pharmacology of Diphenhydramine

  1. Released in 1946 as Benadryl, diphenhydramine was recognized for its sedating effect early on.
  2. Johnson & Johnson, along with other companies, realized they could exploit that sedation as a feature for sleep-aids.
  3. The scientific explanation: diphenhydramine crosses the blood-brain barrier and interferes with H1 receptors, causing drowsiness. Because of its easy penetration into the brain, repeated use builds tolerance.

11.3 The Rise of Diphenhydramine-Based Sleep-Aids

  1. By labeling these products “non habit-forming,” companies fostered a perception that you can take them nightly without consequences.
  2. The global over-the-counter sleep-aid market is huge—$65 billion annually—and rising. The lawsuit claims a significant portion of that revenue is driven by false beliefs about the product’s safety profile.
  3. Studies exist that highlight the link between diphenhydramine and not only tolerance but also potential for misuse—some even describing it as having a “cocaine-like” pattern of dopamine stimulation.

11.4 The Alleged False “Non Habit-Forming” Labeling

  1. The complaint contends that Johnson & Johnson took advantage of consumer desire for “safe” over-the-counter relief.
  2. Tylenol PM is singled out because it blares “non habit-forming” on its front label, an intentional move to increase consumer reliance.
  3. Plaintiff Goodson’s experience is the microcosm of the broader issue: People trust the brand, see the label, buy the product, then—lo and behold—they develop a habit that the brand said they wouldn’t.

12. Countless Americans Trapped by the “Non Habit-Forming” Myth

This isn’t just about Goodson. One in five Americans might regularly resort to an over-the-counter sleep-aid, and many of them are drawn to the big brand promise of Tylenol PM. The phrase “non habit-forming” says: “You’re safe. This is not a potential pitfall. This will not lead to an every-night ritual.”

But here’s the sad truth: For many, it does precisely that. The problem is wide-ranging:

  1. Tolerance: Some individuals report that within two weeks, the same dose no longer knocks them out the way it did initially. So, they up the dose or continue usage out of fear they can’t sleep without it.
  2. Dependence: Even if it isn’t the classic “opioid addiction,” it can still be psychologically habit-forming—especially in a climate where people are desperate for solutions to everyday stress and insomnia.
  3. Potential Overdose: Diphenhydramine overdoses are not trivial. The CDC’s data from 2019–2020 notes a shocking number of overdose deaths in which first-generation antihistamines like diphenhydramine were involved.

Despite a growing body of anecdotal and scientific evidence, Johnson & Johnson (according to the lawsuit) continues the same marketing scheme. For the average consumer, a picture forms: a multi-billion-dollar corporation systematically ignoring the real-world experiences of dependency by pushing the comforting promise of “non habit-forming.”

13. Wealth Disparity and the Sleep Aid Market

Pull out a map of wealth distribution in the U.S., and you’ll likely find that people living in lower socioeconomic brackets face heightened stress, longer working hours, and multiple part-time jobs to make ends meet. The correlation to sleeplessness is straightforward. These same individuals are more prone to pick up an over-the-counter solution, given that they might not have robust health insurance to afford prescription treatments or therapy-based solutions.

Thus, ironically, the “cheap fix” becomes an added burden. If you’re barely scraping by, the last thing you need is an unplanned medical expense resulting from repeated use of “non habit-forming” sleep-aids. This is how the system—under neoliberal capitalism—often traps the poorest. A solution that claims to help them ironically can become an ongoing cost, and potentially a hazard to both health and wallet.

And from the vantage point of wealth disparity, the ones profiting from your nightly purchase are far removed from your local community. In boardrooms, billions of dollars flow through the books, fueling dividends, stock buybacks, and executive bonuses. Meanwhile, you’re left with an over-the-counter sedation that might not be the savior you thought it was.

14. Corporate Ethics and the Real-World Impact

Johnson & Johnson likes to tout itself as the epitome of corporate ethics—a family-friendly brand. Yet, the line between brand marketing and actual practice can be razor-thin. If the allegations are proven true, then the entire façade of ethical practice collapses under the weight of a marketing claim that was demonstrably misleading.

Consider the real-world impact:

  • The Overworked Single Mother: She trusts that “non habit-forming” means she can safely rely on the product for a few stressful weeks, only to discover she can’t get a good night’s rest without popping a diphenhydramine-laced pill.
  • The College Student: Overwhelmed by late-night study sessions, they repeatedly turn to the product, trusting the labeling. By finals week, they’ve doubled the dose to replicate the original effect.
  • The Elderly Consumer: Prone to confusion and sedation, they face a particularly harsh array of side effects—paradoxical stimulation, increased dementia risk, delirium—yet they’ve been told it’s “non habit-forming.”

In each instance, the cost is more than monetary. Sleep deprivation is linked to depression, obesity, type 2 diabetes, cardiovascular disease, and even Alzheimer’s. So if a seemingly benign, widely available product leads to over-dependence or mishandling, we collectively pay the price in increased healthcare burdens and more sick days from work.

15. Consumers’ Advocacy: A Call for Social Justice

Where does social justice factor into this? A big part of the conversation must revolve around consumer advocacy. We need to push regulators, local legislators, and healthcare providers to step in when corporations put profits ahead of transparency.

  • Transparency: If a product can lead to tolerance within 1–2 weeks, label it. Let consumers know the reality.
  • Education: Pharmacies and consumer-advocacy groups should spread awareness of the perils of continuous diphenhydramine use.
  • Stricter Labeling Requirements: If studies show habit formation is possible, it’s time for the FDA to clamp down on misleading phrases.

In a just society, corporations that run elaborate marketing campaigns suggesting absolute safety, while ignoring data on potential habit formation, must be called out and held accountable. This is part of the reason lawsuits like Goodson’s exist—to force transparency.

16. Skepticism About Corporate Change

Let’s not mince words: many of us are skeptical that a corporation the size of Johnson & Johnson will change its ways without a binding legal or financial incentive to do so. One lawsuit might push them to re-label the product, but historically, deep-pocketed corporations often find ways around these hurdles—maybe a small, fine-print disclaimer or burying warnings in package inserts that few read.

Why? Because telling the full truth might impact sales. Under neoliberal capitalism, that’s the cardinal sin. The people in control are beholden to shareholders, not moral or ethical principles. Unless the penalty for ignoring or misrepresenting product hazards outweighs the profit gained from continuing the existing approach, the chance for real transformation is slim.

Nevertheless, legal actions—especially class actions—can move the needle. Public outcry, if it becomes loud enough, can tarnish a brand’s image and result in significant changes. But make no mistake, as this story unfolds, it will likely take intense public scrutiny and potentially massive financial liabilities for Johnson & Johnson to pivot from repeating “non habit-forming” to a more honest label.

17. The Road Toward True Accountability

I’d leave you with this: We must question. We must investigate. We must refuse to accept at face value a corporation’s lazy and grandiose claims, especially when our health is on the line. This is a lesson that extends beyond sleep-aids to every domain where powerful companies profit from the illusions of safety and the comfort of brand recognition.

Johnson & Johnson, with its storied history and supposed commitment to consumer well-being, should have been the last place we’d expect to see alleged false labeling. Yet, here we are. We see a brand that soared to billions in annual revenue while telling consumers, “Don’t worry, you won’t become dependent.”

The lawsuit from Plaintiff Sirreon Goodson pulls back the curtain:

  • In reality, diphenhydramine can and does lead to tolerance and dependence.
  • Millions might be unwittingly risking their health, trusting a label.
  • The overarching system of neoliberal capitalism incentivizes such half-truths because they drive sales.

To rectify this, the courts will investigate, the public will watch, and hopefully, reforms in labeling and marketing will follow. But consumer vigilance is essential. Let’s not forget the communities most affected—lower-income households, the elderly, and individuals whose lives teeter on the edge of mental or physical health crises. They stand to lose the most. It’s for them—and for all consumers—that we must demand corporate accountability.

In the bigger picture, whether we’re talking about corporate pollution, corporate corruption, or corporation’s dangers to public health, the narrative remains the same: Profit is the prime mover until and unless the people demand better.

This is not just a story about Tylenol PM and a “non habit-forming” label. It’s a broader cautionary tale about how easy it is for corporations to leverage carefully chosen words, exploit public trust, and sidestep accountability—until someone like Goodson stands up and says, “Enough.”

If we want to fix this, we can’t simply rely on the corporate world’s self-professed dedication to “corporate social responsibility.” We need robust laws, watchful consumer advocacy, and a readiness to call them out on every exaggeration, every half-truth, and every outright lie. That is what social justice truly demands. It isn’t an easy fight, but it’s a necessary one, especially when the product in question touches something as fundamental as our ability to rest, restore, and function day to day.

We end where we began: People just want a better night’s sleep. They shouldn’t have to sacrifice their health or face hidden dependency traps for that. No brand, no matter how historically trusted, should be allowed to undermine the public’s well-being under the guise of “non habit-forming.” And that’s the honest-to-goodness truth.

The road ahead may be long. Perhaps we will witness Johnson & Johnson revamp its labels, or perhaps the courts will force a more dramatic shift in the entire over-the-counter sleep-aid industry. One can hope. But for now, we shine a bright, unforgiving spotlight on Tylenol PM’s “non habit-forming” myth, urging every consumer to read the fine print—and urging every regulator and lawmaker to remember that the best interest of the public should always come before corporate profit.

Can Johnson & Johnson Listerine Mouthwash Cause Cancer? | J&J
goodson-v-johnson-and-johnson-services-incDownload

💡 Explore Corporate Misconduct by Category

Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.

NOTE:

This website is facing massive amounts of headwind trying to procure the lawsuits relating to corporate misconduct. We are being pimp-slapped by a quadruple whammy:

  1. The Trump regime's reversal of the laws & regulations meant to protect us is making it so victims are no longer filing lawsuits for shit which was previously illegal.
  2. Donald Trump's defunding of regulatory agencies led to the frequency of enforcement actions severely decreasing. What's more, the quality of the enforcement actions has also plummeted.
  3. The GOP's insistence on cutting the healthcare funding for millions of Americans in order to give their billionaire donors additional tax cuts has recently shut the government down. This government shut down has also impacted the aforementioned defunded agencies capabilities to crack down on evil-doers. Donald Trump has since threatened to make these agency shutdowns permanent on account of them being "democrat agencies".
  4. My access to the LexisNexis legal research platform got revoked. This isn't related to Trump or anything, but it still hurt as I'm being forced to scrounge around public sources to find legal documents now. Sadge.

All four of these factors are severely limiting my ability to access stories of corporate misconduct.

Due to this, I have temporarily decreased the amount of articles published everyday from 5 down to 3, and I will also be publishing articles from previous years as I was fortunate enough to download a butt load of EPA documents back in 2022 and 2023 to make YouTube videos with.... This also means that you'll be seeing many more environmental violation stories going forward :3

Thank you for your attention to this matter,

Aleeia (owner and publisher of www.evilcorporations.com)

Also, can we talk about how ICE has a $170 billion annual budget, while the EPA-- which protects the air we breathe and water we drink-- barely clocks $4 billion? Just something to think about....

Evil Corporations
Evil Corporations

Articles written by me are actually written by many different people! We include writers from the legal field, tech, and people who study political theory. Especially people who study political theory.... that makes up about 90% of the guest writers here. If you also want to contribute to this website, then head on over to the Evil Corporations contact page and send over your interest!

Articles: 727